Characterization of Oncology Clinical Trials Using Germline Genetic Data.

ABSTRACT:

Importance

The recent successes of poly-ADP ribose polymerase (PARP) inhibitors and belzutifan support germline genetic data as an exciting, accessible source for biomarkers in cancer treatment. This study hypothesizes, however, that most oncology clinical trials using germline data largely prioritize BRCA1/2 as biomarkers and PARP inhibitors as therapy.

Objective

To characterize past and ongoing oncology trials that use germline data.

Design, setting, and participants

This retrospective cross-sectional study of oncology trials used the Informa Trialtrove database to evaluate trial attributes. Trials using germline information (including the terms germline, hereditary, or inherited in the title, treatment plan, interventions, end points, objectives, results, or notes)

SUBMITTER: Kammula AV 

PROVIDER: S-EPMC9669814 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature